William Blair analyst Sarah Schram initiated coverage of Denali Therapeutics (DNLI) with an Outperform rating. The company is equipped with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback